Keros Therapeutics (KROS) Analyst & Key Data

Analyst Consensus

Buy3 analysts

Buy

Updated Sep 12, 2026

Total Analysts3

Buy

10

Hold

7

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score4.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$11.08

Median Target+83.48%

$20.33

Potential upside vs current price

Current Stock Price

$11.08

Median Target+83.48%

$20.33

Potential upside vs current price

Analyst Consensus

Buy3 analysts

Buy

Updated Sep 12, 2026

Total Analysts3

Buy

10

Hold

7

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score4.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$11.08

Median Target+83.48%

$20.33

Potential upside vs current price

Current Stock Price

$11.08

Median Target+83.48%

$20.33

Potential upside vs current price

Keros Therapeutics, Inc.